The short answer: It can, but it is not common. In the FDA label's placebo-controlled trials, reflux disease was reported in 1.9% of people on Ozempic 0.5 mg and 1.5% on 1 mg, compared with 0% on placebo. Indigestion (dyspepsia) and burping were also more common than on placebo. Large studies suggest GLP-1 drugs raise reflux risk modestly, most likely because they slow how fast the stomach empties.
What does the Ozempic label report for heartburn and reflux?
The FDA-approved Ozempic label on DailyMed (revised May 2026) lists the most common side effects as nausea, vomiting, diarrhea, abdominal pain, and constipation. Heartburn-type symptoms are not on that main list. They appear in section 6.1, among gastrointestinal reactions that occurred in fewer than 5% of patients.
The label gives these rates from its placebo-controlled trials in adults with type 2 diabetes (placebo, 0.5 mg, 1 mg):
- Dyspepsia (indigestion): 1.9%, 3.5%, and 2.7%
- Eructation (burping): 0%, 2.7%, and 1.1%
- Gastroesophageal reflux disease (GERD): 0%, 1.9%, and 1.5%
- Gastritis: 0.8%, 0.8%, and 0.4%
Two points stand out. First, these rates are small, and each group had about 260 people. Second, the 1 mg group did not have higher rates than the 0.5 mg group for these reactions. With groups this size, a difference of 1 or 2 people can move a percentage, so the numbers do not show a clear dose trend.
The label does not break out reflux rates for the 2 mg dose. It says only that overall gastrointestinal reactions occurred in 34% of patients on 2 mg versus 30.8% on 1 mg in the trial that compared them.
Is reflux more common at higher semaglutide doses?
The clearest higher-dose numbers come from Wegovy, which is semaglutide at 2.4 mg once weekly for weight management. The Wegovy label reports these rates in adults with obesity or overweight (placebo versus Wegovy 2.4 mg):
- Dyspepsia: 3% versus 9%
- Eructation: under 1% versus 7%
- GERD: 3% versus 5%
These trials used a different dose and a different population, so the numbers do not transfer directly to Ozempic. They do fit a pattern seen in research: stomach and reflux symptoms tend to be more frequent with higher, weight-loss doses. A 2025 meta-analysis in Gastroenterology found the GERD signal was more pronounced with high-dose formulations, though that subgroup difference was not statistically significant.
If you are still moving up through the Ozempic doses, our Ozempic dosing schedule guide explains the label's 4-week steps.
Why can a slower stomach lead to reflux?
A ring of muscle at the bottom of the esophagus, the lower esophageal sphincter, normally keeps stomach contents down. MedlinePlus explains that when this ring does not close all the way, stomach contents leak back up. That backflow causes heartburn and regurgitation.
Ozempic changes the stomach side of that equation. The label states that semaglutide "causes a delay of early postprandial gastric emptying." Food and acid stay in the stomach longer after a meal. The authors of a 2025 Annals of Internal Medicine study note that delayed gastric emptying is a known risk factor for GERD.
A fuller stomach for a longer time gives acid more chances to push upward, especially if you lie down or eat a large meal. Slower emptying is expected on this drug and is different from gastroparesis. Our article on Ozempic and gastroparesis covers that distinction.
What do larger studies show about GLP-1 drugs and GERD?
The evidence points to a real but modest increase:
- Randomized trials pooled. A 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants found GLP-1 drugs probably increase GERD risk (risk ratio 2.19). In absolute terms, that was about 4 more cases per 1,000 people.
- Real-world diabetes data. The Annals study followed 24,708 new GLP-1 users and 89,096 new SGLT-2 inhibitor users in the U.K. GLP-1 users had a 27% higher relative risk of GERD (risk ratio 1.27). The absolute difference was 0.7 cases per 100 patients over 3 years.
- Short-acting versus long-acting drugs. A 2024 study in Gut found a higher risk of erosive reflux disease with short-acting GLP-1 drugs such as liraglutide and exenatide. Long-acting drugs did not show that increase (hazard ratio 0.994).
Semaglutide is long-acting, with a half-life of about 1 week per the label. The studies do not fully agree, and observational data cannot prove cause. There is also an offsetting effect. The American College of Gastroenterology (ACG) GERD guideline strongly recommends weight loss for people with overweight or obesity to improve reflux symptoms.
What can help heartburn while you take Ozempic?
The ACG guideline and MedlinePlus list steps that fit well with how Ozempic works:
- Stop eating 2 to 3 hours before bed. ACG suggests avoiding meals in that window. With slower emptying, this may matter more than usual.
- Eat smaller meals. A smaller meal puts less volume in a stomach that is already emptying slowly.
- Raise the head of your bed if symptoms are worse at night. ACG suggests this for nighttime reflux.
- Find your trigger foods. The guideline lists common culprits such as high-fat foods, chocolate, peppermint, alcohol, carbonated drinks, and spicy or acidic foods. Our list of foods to avoid on Ozempic overlaps with many of these.
- Avoid tobacco. ACG suggests avoiding smoking for reflux symptoms.
- Ask about over-the-counter options. MedlinePlus notes antacids give quick but short relief. Acid reducers such as H2 blockers and proton pump inhibitors (PPIs) work more slowly and last longer.
For classic heartburn with no warning signs, ACG recommends a clinician-guided 8-week trial of a once-daily PPI taken before a meal. Talk with your prescriber or pharmacist before starting one.
Do not stop Ozempic or change your dose on your own. The label increases the dose only after at least 4 weeks at each step. Your prescriber can decide whether a slower schedule makes sense. Also tell your prescriber about every medicine you take by mouth. The label says delayed emptying may affect how oral medicines are absorbed, though tested medicines showed no clinically relevant change.
When is heartburn on Ozempic a warning sign?
Mild heartburn after a large meal is one thing. Some symptoms need prompt medical attention.
Call your provider soon if you have any of these, which ACG and MedlinePlus list as reasons for further evaluation:
- Trouble swallowing, pain with swallowing, or food that feels stuck behind the breastbone
- Vomiting that keeps coming back
- Any sign of bleeding, or anemia found on a blood test
- Choking, hoarseness, or a cough that will not go away
- Heartburn that does not improve with lifestyle changes or medicine
Weight loss is a listed alarm sign for reflux, and Ozempic often causes weight loss. Tell your provider if you are losing weight because eating hurts or food will not go down.
Seek emergency care in two situations. MedlinePlus notes that heart attack pain can feel like "bad indigestion." It also says people with diabetes may have little or no chest pain during a heart attack. Call 911 for chest pressure, shortness of breath, sweating, or pain spreading to the arm, jaw, or back. The Ozempic label also warns about pancreatitis: severe stomach-area pain that will not go away and may spread to the back.
The bottom line
Ozempic can cause heartburn, indigestion, and reflux, but the label shows these in fewer than 4% of trial participants at each dose. Slower stomach emptying is the most likely reason. Research links GLP-1 drugs to a modest rise in GERD risk, with higher rates at weight-loss doses. Smaller meals, no food for 2 to 3 hours before bed, and a raised bed head are reasonable first steps. For more on how the whole GLP-1 drug class affects digestion, see glp1.md. Trouble swallowing, bleeding, or chest pain needs medical attention right away.
Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your prescriber before starting acid-reducing medicine or changing your Ozempic dose.